> Details

Ettrich, Thomas Jens; Berger, Andreas Wolfgang; Decker, Thomas; Hofheinz, Ralf; Heinemann, Volker; Hoffmann, Thomas; Hebart, Holger Frithjof; Herrmann, Thomas; Hannig, Carla Verena; Buechner-Steudel, Petra; Guethle, Melanie; Bartholomaeus, Hanna; Beutel, Alica; Perkhofer, Lukas; Seufferlein, Thomas

Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO
  • Contributor: Ettrich, Thomas Jens; Berger, Andreas Wolfgang; Decker, Thomas; Hofheinz, Ralf; Heinemann, Volker; Hoffmann, Thomas; Hebart, Holger Frithjof; Herrmann, Thomas; Hannig, Carla Verena; Buechner-Steudel, Petra; Guethle, Melanie; Bartholomaeus, Hanna; Beutel, Alica; Perkhofer, Lukas; Seufferlein, Thomas
  • Published: American Society of Clinical Oncology (ASCO), 2019
  • Published in: Journal of Clinical Oncology, 37 (2019) 4_suppl, Seite 666-666
  • Language: English
  • DOI: 10.1200/jco.2019.37.4_suppl.666
  • ISSN: 0732-183X; 1527-7755
  • Origination:
  • Footnote:
  • Description: 666 Background: Anti-VEGF agents plus chemotherapy improve PFS of patients with mCRC in the first- and second-line-setting. During this treatment tumour angiogenesis is driven by other factors but VEGF. Nintedanib, a triple angiokinase inhibitor of VEGFR-1-3, FGFR-1/-3 and PDGFR-α/-β, thereby additionally targets angiogenic escape mechanisms upon resistance to anti-VEGF treatment. The TRICC-C trial evaluates the combination of mFOLFOX6 plus Nintedanib. Final results of the randomized phase II trial are presented. Methods: Patients with mCRC having received one line of non-oxaliplatin containing palliative chemotherapy, with an ECOG-PS of 0/1 were randomized 1:1 in a double-blind design to receive: mFOLFOX6 plus Nintedanib (2 x 200 mg p.o./d, d1-d14) or placebo, respectively, repeated every 14 days. Primary endpoint was PFS. Secondary endpoints were ORR, OS and safety. Patients who received at least one dose of trial medication were included in the efficacy and safety analyses. Results: From 12/2012 to 5/2016 53 patients (scheduled n = 180) were randomized. The trial was terminated prematurely due to slow accrual. Compared to mFOLFOX6 plus placebo (F+P), the combination of mFOLFOX6 plus Nintedanib (F+N) improved mPFS (F+P: 4.6 vs. F+N: 8.1 mo.; HR 0.65; 95% CI 0.32-1.30; p = 0.2156), mOS (F+P: 9.9 vs. F+N: 17.1 mo.; HR 1.03, 95% CI 0.48-2.23; p = 0.9387) and DCR (F+P: 50 vs. F+N: 66,7%; p = 0.2709). ORR was comparable in both arms (F+N: 3.8 vs. F+P: 3.7%). Toxicity was low to moderate without major differences between both arms except G 3/4 neutropenia (F+N: 19%, F+P: 12%) and GI disorders (F+N: 23%, F+P: 15%). Conclusions: Final results suggest a PFS, OS and DCR benefit for mFOLFOX6 + Nintedanib in the second-line therapy of mCRC. Due to the premature termination of the trial there was no statistical significance demonstrable. Showing no clinically significant PFS-benefit in the first-line situation (mFOLFOX6 plus Nintedanib/Bevacizumab, Ann Oncol. 2015) or the last line as single agent, respectively (ESMO 2016) the TRICC-C results suggests that Nintedanib plus mFOLFOX6 could be an interesting therapeutic option for the second-line situation. Clinical trial information: NCT01362361.
  • Access State: Open Access